Elicio Therapeutics (ELTX) Other Non-Current Liabilities (2022 - 2026)

Elicio Therapeutics has reported Other Non-Current Liabilities for 5 years, with the latest figure at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 21.51% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $3.6 million (up 21.51% YoY), and the FY2025 full-year result was $2.6 million, down 7.53% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $3.6 million, up from $2.6 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $23.2 million in Q3 2024, with the low at $11000.0 in Q4 2023.
• Historically, Other Non-Current Liabilities has averaged $4.3 million across 5 years, with a median of $2.9 million in 2024.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 25609.09% — and 2025, when it slumped 85.89%.
• Elicio Therapeutics' Other Non-Current Liabilities stood at $81000.0 in 2022, then slumped by 86.42% to $11000.0 in 2023, then soared by 25609.09% to $2.8 million in 2024, then dropped by 7.53% to $2.6 million in 2025, then surged by 37.63% to $3.6 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $3.6 million (Q1 2026), $2.6 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.